(Q35669840)

9 August 2017

1 reference

title

Budesonide/formoterol: in chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

9 August 2017

main subject

1 reference

inferred from title

budesonide/formoterol

1 reference

2

Caroline M Perry

1 reference

9 August 2017

3

Gillian M Keating

1 reference

9 August 2017

Neil A Reynolds

1

1 reference

9 August 2017

publication date

1 January 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

64

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

431-41; discussion 433-4

1 reference

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

9 August 2017

cites work

1 reference

12 December 2020

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

1 reference

12 December 2020

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

1 reference

12 December 2020

Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide

1 reference

12 December 2020

Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data

1 reference

12 December 2020

Chronic obstructive pulmonary disease

1 reference

12 December 2020

Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole

1 reference

12 December 2020

Outpatient management of chronic obstructive pulmonary disease

1 reference

12 December 2020

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

12 December 2020

Stable chronic obstructive pulmonary disease

1 reference

12 December 2020

Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update

1 reference

12 December 2020

Chronic obstructive pulmonary disease

1 reference

12 December 2020

Inhaled budesonide/formoterol combination

1 reference

12 December 2020

Interpreting thresholds for a clinically significant change in health status in asthma and COPD.

1 reference

12 December 2020

Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids

1 reference

12 December 2020

Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid

1 reference

12 December 2020

Formoterol: a review of its use in chronic obstructive pulmonary disease

1 reference

12 December 2020

Guidelines for the management of chronic obstructive pulmonary disease. Working Group of the South African Pulmonology Society

1 reference

12 December 2020

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society

1 reference

12 December 2020

Clinical pharmacokinetics of inhaled budesonide

1 reference

12 December 2020

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive

1 reference

12 December 2020

Interactions between corticosteroids and beta agonists

1 reference

12 December 2020

Mechanisms of action of glucocorticoids in asthma

1 reference

12 December 2020

Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

1 reference

12 December 2020

Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma

1 reference

12 December 2020

Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler

1 reference

12 December 2020

Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

1 reference

12 December 2020

Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders

1 reference

12 December 2020

Chronic obstructive pulmonary disease international guidelines.

1 reference

12 December 2020

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

1 reference

12 December 2020

Pharmacological factors that influence the choice of inhaled corticosteroids

1 reference

12 December 2020

Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro

1 reference

12 December 2020

BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS

1 reference

12 December 2020

Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice

1 reference

12 December 2020

10.2165/00003495-200464040-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

9 August 2017

1028116866

0 references

1 reference